Angion Biomedica Corp (ANGN): Price and Financial Metrics

Angion Biomedica Corp (ANGN): $1.50

0.18 (+13.64%)

POWR Rating

Component Grades













Add ANGN to Watchlist
Sign Up

Industry: Biotech



in industry

ANGN Stock Price Chart Interactive Chart >

Price chart for ANGN

ANGN Price/Volume Stats

Current price $1.50 52-week high $16.04
Prev. close $1.32 52-week low $1.08
Day low $1.31 Volume 199,900
Day high $1.56 Avg. volume 95,189
50-day MA $1.69 Dividend yield N/A
200-day MA $4.41 Market Cap 44.94M

Angion Biomedica Corp (ANGN) Company Bio

Angion Biomedica Corp. operates as a late-stage biopharmaceutical company. The Company focuses on the discovery, development, and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases. Angion Biomedica serves customers in the State of New York.

ANGN Latest News Stream

Event/Time News Detail
Loading, please wait...

ANGN Latest Social Stream

Loading social stream, please wait...

View Full ANGN Social Stream

Latest ANGN News From Around the Web

Below are the latest news stories about Angion Biomedica Corp that investors may wish to consider to help them evaluate ANGN as an investment opportunity.

Angion Biomedica: Selling At Cash Value

Within any important issue, there are always aspects no one wishes to discuss.”― George Orwell Today, we take our first in-depth look at a small biotech developmental firm that went public just less than a year ago, but is already deep in 'Busted IPO' territory. It popped up on our...

Busted IPO Forum on Seeking Alpha | February 7, 2022

Angion Biomedica (ANGN) Investor Presentation - Slideshow

No summary available.

Seeking Alpha | January 11, 2022

Trade Alert: The President Of Angion Biomedica Corp. (NASDAQ:ANGN), Jay Venkatesan, Has Just Spent US$730k Buying 24% More Shares

Those following along with Angion Biomedica Corp. ( NASDAQ:ANGN ) will no doubt be intrigued by the recent purchase of...

Yahoo | January 5, 2022

Angion Provides Corporate Update and Announces Participation in Upcoming Investor Conference

-- First patient enrolled in the Phase 2 trial of ANG-3070 in primary proteinuric kidney diseases -- Angion will end 2021 with approximately $88.8 million in cash and cash equivalents UNIONDALE, N.Y., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Angion Biomedica Corp (NASDAQ:ANGN), a biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address fibrotic diseases and acute organ injuries, today provided a corporate update and announced

Yahoo | January 4, 2022

H.C. Wainwright Sticks to Its Buy Rating for Angion Biomedica (ANGN)

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Angion Biomedica (ANGN – Research Report) today and set a price target of $50.00. The company's shares closed last Friday at $2.90, close to its 52-week low of $2.28. According to, Selvaraju has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -18.5% and a 25.2% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Aquestive Therapeutics, Oncternal Therapeutics, and Inovio Pharmaceuticals. Angion Biomedica has an analyst consensus of Strong Buy, with a price target consensus of $21.00.

Brian Anderson on TipRanks | January 3, 2022

Read More 'ANGN' Stories Here

ANGN Price Returns

1-mo 17.19%
3-mo -27.18%
6-mo -58.33%
1-year -90.28%
3-year N/A
5-year N/A
YTD -48.28%
2021 N/A
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.6284 seconds.